Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,090,000 ...
4 analysts have shared their evaluations of Century Therapeutics IPSC during the recent three ... analysts have established 12-month price targets, indicating an average target of $6.25, along ...
The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating ... has allowed Dr. Fossati’s lab to identify and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback